Last 48 quarters of trend data · Healthcare · Specialty & Generic Drugs
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 4.87 | 2.76 | 3.40 | 3.66 | — | 1.42 | 1.28 | — | 78.55 | 45.18 | — | — | — | 29.36 | — | 10.52 | 11.91 | 9.59 | 13.73 | 15.72 | 11.66 |
| — | +93.6% | +165.1% | — | — | -96.8% | — | — | — | +53.9% | — | — | — | +206.1% | — | -33.1% | +2.2% | -0.1% | +919.6% | +40.7% | +10.6% | |
| P/S Ratio | 1.81 | 1.24 | 1.54 | 1.37 | 3.14 | 0.48 | 0.34 | 1.44 | 1.96 | 1.80 | 2.75 | 4.59 | 3.80 | 3.96 | 3.85 | 4.72 | 5.35 | 4.40 | 5.48 | 6.11 | 4.12 |
| — | +159.6% | +352.8% | -4.5% | +60.0% | -73.5% | -87.6% | -68.6% | -48.3% | -54.5% | -28.7% | -2.8% | -29.1% | -10.0% | -29.8% | -22.8% | +29.8% | -15.4% | +8.4% | +19.7% | +4.6% | |
| P/B Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 2.78 | 3.52 | 3.23 | 4.00 | 4.61 | 3.19 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -39.7% | +10.3% | -13.1% | -2.7% | -72.0% | -89.1% | |
| P/FCF | 5.69 | — | 2.99 | 28.56 | 2.01 | 1.22 | — | 2.97 | 11.68 | 16.72 | 7.76 | 7.65 | 12.53 | 13.88 | 11.82 | 6.13 | 7.24 | 6.92 | 8.70 | 9.30 | 7.49 |
| — | — | — | +861.9% | -82.8% | -92.7% | — | -61.2% | -6.8% | +20.5% | -34.4% | +24.8% | +73.0% | +100.6% | +35.9% | -34.1% | -3.3% | -3.9% | -19.7% | +51.0% | -16.1% | |
| EV / EBITDA | 4.36 | 1.56 | 3.18 | 3.30 | 34.99 | 2.21 | 3.41 | — | 9.55 | 11.35 | 15.42 | 42.11 | 15.79 | 12.37 | — | 6.78 | 7.47 | 6.36 | 9.11 | 10.00 | 7.84 |
| — | -29.6% | -6.9% | — | +266.3% | -80.5% | -77.9% | — | -39.5% | -8.3% | — | +520.8% | +111.3% | +94.5% | — | -32.2% | -4.7% | -18.8% | +15.0% | -0.1% | -15.7% | |
| EV / EBIT | 9.30 | 1.56 | 3.13 | 3.24 | 29.42 | 2.26 | 3.37 | — | 9.28 | 11.08 | 14.91 | 42.39 | 15.05 | 14.55 | 10.24 | 6.08 | 6.96 | 6.13 | 9.12 | 10.06 | 8.24 |
| — | -31.1% | -6.9% | — | +217.0% | -79.6% | -77.4% | — | -38.4% | -23.9% | +45.7% | +597.5% | +116.3% | +137.3% | +12.3% | -39.6% | -15.6% | -22.2% | +13.9% | +0.3% | -9.2% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | 99.6% | 100.0% | 99.6% | 99.5% | 33.3% | 100.0% | 67.4% | 100.0% | 65.5% | 100.0% | 99.6% | 81.6% | 99.7% | 99.7% | 99.7% | 99.6% | 88.9% | 99.7% |
| — | +0.4% | +0.6% | +198.8% | 0.0% | +47.7% | -0.5% | -49.1% | 0.0% | -32.3% | +22.6% | -34.3% | +0.3% | -0.1% | -18.1% | +12.2% | -0.0% | +11.4% | +12.8% | +7.7% | +0.5% | |
| Operating Margin | 40.1% | 70.0% | 70.2% | 68.1% | 13.7% | 63.6% | 52.9% | -70.7% | 34.8% | 28.0% | 26.5% | 14.7% | 32.0% | 42.7% | -1008.7% | 57.8% | 63.8% | 63.0% | 57.2% | 59.3% | 48.3% |
| — | +10.0% | +32.7% | +196.3% | -60.5% | +127.4% | +99.8% | -580.7% | +8.8% | -34.5% | +102.6% | -74.5% | -49.9% | -32.2% | -1862.2% | -2.6% | +32.0% | +0.3% | -8.5% | +16.1% | +9.7% | |
| Net Margin | 8.1% | 45.0% | 45.4% | 38.3% | -4.8% | 32.8% | 27.7% | -90.9% | 2.5% | 4.0% | -0.9% | -5.6% | -0.9% | 13.5% | -989.2% | 43.9% | 45.6% | 46.3% | 38.1% | 39.8% | 35.3% |
| — | +37.0% | +63.9% | +142.1% | -291.5% | +724.9% | +3138.7% | -1534.8% | +369.4% | -70.4% | +99.9% | -112.7% | -102.0% | -70.9% | -2693.8% | +10.4% | +29.1% | -14.0% | -89.9% | -11.5% | -4.6% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -590.0% | 6.7% | 7.9% | 9.0% | 7.1% | 6.9% | 7.0% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | -8458.6% | -2.6% | +12.6% | -12.5% | -94.4% | -85.1% | -94.5% | |
| ROA | 6.4% | 20.8% | 14.3% | 9.8% | -0.6% | 10.8% | 7.0% | -11.0% | 0.6% | 0.9% | -0.2% | -0.9% | -0.2% | 2.7% | -120.8% | 4.1% | 4.6% | 5.0% | 3.6% | 3.5% | 3.8% |
| — | +91.6% | +102.4% | +188.9% | -194.2% | +1067.9% | +3517.2% | -1105.3% | +378.9% | -65.8% | +99.8% | -122.6% | -104.8% | -45.5% | -3454.2% | +15.4% | +21.7% | -6.7% | -92.6% | -49.1% | -54.4% | |
| ROIC | 54.0% | — | 37.7% | 38.8% | 3.1% | 29.8% | 19.1% | -11.9% | 11.1% | 9.0% | 8.3% | 3.2% | 9.7% | 12.2% | -240.8% | 11.4% | 12.2% | 11.7% | 9.2% | 9.4% | 9.1% |
| — | — | +97.5% | +425.5% | -71.9% | +231.7% | +130.0% | -471.9% | +14.7% | -26.3% | +103.4% | -71.8% | -20.3% | +3.8% | -2708.9% | +20.9% | +34.0% | +15.1% | -42.1% | -61.2% | -65.0% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.59 | 0.64 | 0.70 | 0.78 | 1.04 | 0.79 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -43.3% | -18.8% | -13.2% | -14.0% | -75.1% | -89.2% | |
| Debt / EBITDA | 4.96 | 0.12 | 4.98 | 8.19 | 85.24 | 7.65 | 13.15 | — | 18.75 | 23.52 | 25.12 | 59.86 | 18.77 | 15.08 | — | 6.89 | 6.05 | 6.04 | 7.43 | 9.22 | 8.35 |
| — | -98.4% | -62.2% | — | +354.7% | -67.5% | -47.7% | — | -0.1% | +56.0% | — | +769.3% | +210.0% | +149.5% | — | -25.3% | -27.5% | -15.8% | +4.7% | -8.0% | -4.6% | |
| Current Ratio | 1.13 | 6.51 | 6.06 | 1.41 | 1.13 | 1.13 | 0.82 | 3.34 | 4.69 | 3.62 | 3.92 | 0.82 | 0.84 | 0.90 | 1.04 | 36.34 | 30.58 | 25.78 | 26.52 | 4.82 | 4.61 |
| — | +476.2% | +635.2% | -57.9% | -75.9% | -68.8% | -78.9% | +304.9% | +455.6% | +300.1% | +276.5% | -97.7% | -97.2% | -96.5% | -96.1% | +654.3% | +563.6% | +440.1% | +474.5% | -78.9% | -70.1% | |
| Quick Ratio | 1.13 | 6.51 | 6.06 | 1.41 | 1.13 | 1.13 | 0.82 | 3.34 | 4.69 | 3.62 | 3.92 | 0.82 | 0.84 | 0.90 | 1.04 | 36.34 | 30.53 | 25.78 | 26.52 | 4.82 | 4.61 |
| — | +476.2% | +635.2% | -57.9% | -75.9% | -68.8% | -78.9% | +304.9% | +455.6% | +300.1% | +276.5% | -97.7% | -97.2% | -96.5% | -96.1% | +654.3% | +562.5% | +440.1% | +474.5% | -78.9% | -70.1% | |
| Interest Coverage | 3.14 | 15.13 | 11.24 | 8.13 | 1.06 | 9.06 | 5.53 | -1.31 | 3.69 | 2.84 | 3.53 | 1.58 | 4.75 | 4.25 | 30.45 | 44.13 | 48.36 | 46.87 | 25.37 | 24.71 | 6.82 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying IRWD stock.
Ironwood Pharmaceuticals, Inc.'s current P/E is 4.9x. The average P/E over the last 3 quarters is 3.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Ironwood Pharmaceuticals, Inc.'s current operating margin is 40.1%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Ironwood Pharmaceuticals, Inc.'s business trajectory between earnings reports.